

NEWSLETTER

CHEMICAL & PHARMACEUTICAL

18 - 24 May 2026



EU Issues Preliminary Anti-dumping Ruling on Chinese Polyester Spunbond Nonwoven Fabric

According to the Ministry of Commerce of China, on May 13, 2026, the European Commission issued a preliminary ruling on the anti-dumping investigation of Chinese polyester spunbond nonwoven fabric, deciding to impose provisional anti-dumping measures from May 14, imposing anti-dumping duties ranging from 45.6% to 50.0% on polyester spunbond nonwoven fabric originating from China. **(ChemNet Chemical Industry Headlines)**

EU Issues Preliminary Anti-dumping Ruling on Alkylphosphonic Acids and Their Sodium Salts

China's Ministry of Commerce announced that on May 13, 2026, the European Commission issued a preliminary ruling on the anti-dumping investigation of alkylphosphonic acids and their sodium salts from China, deciding to impose provisional anti-dumping measures from May 14, imposing anti-dumping duties ranging from 182.9% to 219.4% on alkylphosphonic acids and their sodium salts originating in China. **(ChemNet Chemical Industry Headlines)**

Hebei Province Announces Expansion Plans for Two Chemical Industrial Parks

The Hebei Provincial Department of Industry and Information Technology issued a public notice confirming the expansion plans for the Xingtai Xuyang Economic Development Zone Chemical Industrial Park and the Dongxing Industrial Zone of the Cangzhou Bohai New Area Nandagang Industrial Park. The total area of the two parks will increase by approximately 143.21 hectares after the expansion. **(ChemNet Chemical Industry Headlines)**

World's first AI-guided drug combination trial for resistant cancers shows 40% response rate

A nationwide Phase 2 trial using an AI platform to design personalized drug combinations for treatment-resistant cancers has reported promising results. The platform analyzes a patient's tumor genomics and previous treatment data to recommend non-standard drug pairings. The trial achieved a 40% objective response rate in patients who had exhausted conventional options. **(National Cancer Center)**

National policy extends market exclusivity for pediatric rare disease drugs

China has implemented a new policy granting an additional two years of market exclusivity to new drugs approved for pediatric rare diseases. The incentive aims to stimulate R&D investment in an underserved area with high unmet need. The policy applies to both domestic and international manufacturers and is linked to a streamlined priority review pathway. **(National Medical Products Administration)**